<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Genes involved in XX differences/disorders of sex development (DSD) that are associated with atypical genital appearance</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Genes involved in XX differences/disorders of sex development (DSD) that are associated with atypical genital appearance</h1>
<div class="graphic"><div class="figure"><div class="ttl">Genes involved in XX differences/disorders of sex development (DSD) that are associated with atypical genital appearance</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="5" width="12%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Disorder<br/> (MIM phenotype)</td> <td class="subtitle1">Gene</td> <td class="subtitle1">Protein</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">Gonad</td> <td class="subtitle1">Müllerian structures</td> <td class="subtitle1">Associated features/variant phenotypes</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Adrenal overproduction of androgens (genes involved in adrenal hormone synthesis)</td> </tr> <tr> <td class="indent1">21-alpha-hydroxylase deficiency<br/> (<a href="https://www.omim.org/entry/201910" target="_blank">MIM #201910</a>)</td> <td><a href="https://www.omim.org/entry/613815" target="_blank"><em>CYP21A2</em></a></td> <td>Enzyme (converts 17OHP to 11-deoxycortisol)</td> <td>AR</td> <td>Ovary</td> <td class="centered">+</td> <td>CAH; phenotypic spectrum from severe salt-losing forms associated with adrenal failure to simple virilizing forms with compensated adrenal function. 17OHP markedly elevated.</td> </tr> <tr> <td class="indent1">11-beta-hydroxylase deficiency<br/> (<a href="https://www.omim.org/entry/202010" target="_blank">MIM #202010</a>)</td> <td><a href="https://www.omim.org/entry/610613" target="_blank"><em>CYP11B1</em></a></td> <td>Enzyme (converts 11-deoxycorticosterone to corticosterone and 11-deoxycortisol to cortisol)</td> <td>AR</td> <td>Ovary</td> <td class="centered">+</td> <td>CAH; hypertension caused by 11-deoxycortisol and 11-deoxycorticosterone. 17OHP often moderately elevated.</td> </tr> <tr> <td class="indent1">3-beta-hydroxysteroid dehydrogenase type 2 deficiency<br/> (<a href="https://www.omim.org/entry/201810" target="_blank">MIM #201810</a>)</td> <td><a href="https://www.omim.org/entry/613890" target="_blank"><em>HSD3B2</em></a></td> <td>Enzyme (converts pregnenolone to progesterone, 17-hydroxypregnenolone to 17OHP, and DHEA to androstenedione)</td> <td>AR</td> <td>Ovary</td> <td class="centered">+</td> <td>CAH; primary adrenal insufficiency; partial virilization caused by DHEAS. 17-hydroxypregnenolone-to-cortisol ratio markedly elevated. 17OHP often moderately elevated.</td> </tr> <tr> <td class="indent1">P450 oxidoreductase deficiency<br/> (<a href="https://www.omim.org/entry/613571" target="_blank">MIM #613571</a>)<br/> (<a href="https://www.omim.org/entry/201750" target="_blank">MIM #201750</a>)</td> <td><a href="https://www.omim.org/entry/124015" target="_blank"><em>POR</em></a></td> <td>Cofactor for 17-alpha-hydroxylase, 21-hydroxylase, and aromatase</td> <td>AR</td> <td>Ovary</td> <td class="centered">+</td> <td>CAH with combined features of 21-hydroxylase deficiency, 17-alpha-hydroxylase/17,20-lyase deficiency, and aromatase deficiency. May be associated with craniosynostosis and limb abnormalities (Antley-Bixler syndrome). May cause mild maternal virilization during pregnancy.</td> </tr> <tr> <td class="indent1">Glucocorticoid resistance (atypical)<br/> (<a href="https://www.omim.org/entry/615962" target="_blank">MIM #615962</a>)</td> <td><a href="https://www.omim.org/entry/138040" target="_blank"><em>NR3C1</em></a> (glucocorticoid receptor)</td> <td>Nuclear receptor TF</td> <td>AR</td> <td>Ovary</td> <td class="centered">+</td> <td>Elevated adrenocorticotropin, 17OHP, and cortisol; inadequate suppression by dexamethasone.</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Gonadal overproduction of androgens (XX testicular or ovotesticular DSD) due to mutations involved in gonadal (ovarian) development</td> </tr> <tr> <td class="indent1">46,XX testicular/ovotesticular DSD, <em>SRY</em>-positive<br/> (<a href="https://www.omim.org/entry/400045" target="_blank">MIM #400045</a>)</td> <td><a href="https://www.omim.org/entry/480000" target="_blank"><em>SRY</em></a> (sex-determining region on the Y chromosome)</td> <td>TF</td> <td>Translocation</td> <td>Testis or ovotestis</td> <td class="centered">–</td> <td>Presence of <em>SRY</em> in an XX individual (eg, due to translocation to the X chromosome) activates testicular pathways in the developing gonad.</td> </tr> <tr> <td class="indent1"><em>NR5A1</em> mutation<br/> (<a href="https://www.omim.org/entry/617480" target="_blank">MIM #617480</a>)</td> <td><a href="https://www.omim.org/entry/184757" target="_blank"><em>NR5A1</em></a> (<em>SF1</em>)</td> <td>TF</td> <td>AD</td> <td>Testis or ovotestis</td> <td class="centered">+/–</td> <td><em>NR5A1</em> (<em>SF1</em>) mediates gonadal development and testicular differentiation, and <em>NR5A1</em> variants are responsible for 10 to 15% of XX testicular or ovotesticular DSD.</td> </tr> <tr> <td class="indent1"><em>SOX9</em> overexpression<br/> (<a href="https://www.omim.org/entry/278850" target="_blank">MIM #278850</a>)</td> <td><a href="https://www.omim.org/entry/608160" target="_blank"><em>SOX9M</em></a></td> <td>TF</td> <td>dup17q24</td> <td>Not determined</td> <td class="centered">–</td> <td><em>SOX9</em> encodes a transcription factor that is both necessary and sufficient for testicular development.</td> </tr> <tr> <td class="indent1"><em>SOX3</em> overexpression<br/> (<a href="https://www.omim.org/entry/300833" target="_blank">MIM #300833</a>)</td> <td><a href="https://www.omim.org/entry/313430" target="_blank"><em>SOX3</em></a></td> <td>TF</td> <td>Duplication</td> <td>Testis</td> <td class="centered"> </td> <td>Inappropriate expression of <em>SOX3</em> activates testicular pathways in the developing gonad.</td> </tr> <tr> <td class="indent1"><em>WNT4</em> deficiency<br/> (<a href="https://www.omim.org/entry/611812" target="_blank">MIM #611812</a>)</td> <td><a href="https://www.omim.org/entry/603490" target="_blank"><em>WNT4</em></a></td> <td>Signaling molecule</td> <td>AR</td> <td> </td> <td class="centered"> </td> <td>SERKAL syndrome ("sex reversal" with dysgenesis of kidneys, adrenals, and lungs).</td> </tr> <tr> <td class="indent1"><em>RSPO1</em> deficiency<br/> (<a href="https://www.omim.org/entry/610644" target="_blank">MIM #610644</a>)</td> <td><a href="https://www.omim.org/entry/609595" target="_blank"><em>RSPO1</em></a></td> <td>Regulator of <em>WNT</em> signaling</td> <td> </td> <td> </td> <td class="centered"> </td> <td>Palmoplantar keratosis.</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Ovarian overproduction of androgens</td> </tr> <tr> <td class="indent1">Aromatase deficiency<br/> (<a href="https://www.omim.org/entry/613546" target="_blank">MIM #613546</a>)</td> <td><a href="https://www.omim.org/entry/107910" target="_blank"><em>CYP19A1</em></a></td> <td>Enzyme (converts androgens to estrogens)</td> <td>AR</td> <td>Ovary</td> <td class="centered">+</td> <td>Maternal virilization during pregnancy due to deficiency in placental aromatase. Absent breast development in offspring at puberty, except in partial cases.</td> </tr> </tbody></table></div><div class="graphic_lgnd">Chromosomal rearrangements likely to include key genes are included.</div><div class="graphic_footnotes">DSD: differences (or disorders) of sex development; 17OHP: 17-hydroxyprogesterone; AR: autosomal recessive; CAH: congenital adrenal hyperplasia; DHEA: dehydroepiandrosterone; DHEAS: dehydroepiandrosterone sulfate; TF: transcription factor; AD: autosomal dominant (or de novo mutation).</div><div class="graphic_reference">Adapted from:
<ol>
<li>Barbaro M, Wedell A, Nordenström A. Disorders of sex development. Semin Fetal Neonatal Med 2011; 16:119.</li>
<li>Lee PA, Houk CP, Ahmed SF, Hughes IA. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics 2006; 118:e488.</li>
</ol></div><div id="graphicVersion">Graphic 56975 Version 24.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
